Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia

Colin A. Shanks*, Michael J Avram, Robert J. Fragen, Dorene A. O'Hara

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Vecuronium was administered to two patient groups as a single intravenous dose, 60 μg/kg, combined with an infusion, 1 μg/min/kg. Anesthesia was maintained for the first group with a halothane-nitrous oxide technique; the second group received fentanyl-barbiturate-tranqudizer-nitrous oxide. As the infusion ended, plasma vecuronium concentrations were 0.34 (± 0.10) μg/ml for the halothane group and 0.32 (± 0.07) μg/ml for the fentanyl group, associated with 93% (± 8) and 88% (± 10) twitch depression, respectively. Vecuronium plasma concentration-time data were combined with the simultaneous intensities of neuromuscular blockade to model the kinetic-dynamic values for each patient. For the halothane group the steady-state volume was 0.21 (±0.04) L/kg, the clearance was 2.9 (±0.1) ml/min/kg, and the elimination half-life was 100 (± 36) minutes; for the fentanyl group these were 0.20 (± 0.08) L/kg, 3.2 (±0.1) ml/min/kg, and 84 (±43) minutes, respectively. Plasma concentrations associated with 50% blockade averaged 0.2 μg/ml for both groups. Neither the pharmacoldnetics nor the pharmacodynamics of vecuronium in humans differed between these two patient groups.

Original languageEnglish (US)
Pages (from-to)459-464
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume42
Issue number4
DOIs
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacokinetics and pharmacodynamics of vecuronium administered by bolus and infusion during halothane or balanced anesthesia'. Together they form a unique fingerprint.

Cite this